CA2580643C - Use of tellurium compounds for inhibition of interleukin-converting enzyme - Google Patents

Use of tellurium compounds for inhibition of interleukin-converting enzyme Download PDF

Info

Publication number
CA2580643C
CA2580643C CA2580643A CA2580643A CA2580643C CA 2580643 C CA2580643 C CA 2580643C CA 2580643 A CA2580643 A CA 2580643A CA 2580643 A CA2580643 A CA 2580643A CA 2580643 C CA2580643 C CA 2580643C
Authority
CA
Canada
Prior art keywords
tellurium
group
inhibition
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2580643A
Other languages
English (en)
French (fr)
Other versions
CA2580643A1 (en
Inventor
Michael Albeck
Benjamin Sredni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cassiopea SpA
Original Assignee
Cassiopea SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassiopea SpA filed Critical Cassiopea SpA
Publication of CA2580643A1 publication Critical patent/CA2580643A1/en
Application granted granted Critical
Publication of CA2580643C publication Critical patent/CA2580643C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C395/00—Compounds containing tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
CA2580643A 2004-09-17 2005-09-15 Use of tellurium compounds for inhibition of interleukin-converting enzyme Expired - Fee Related CA2580643C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61066004P 2004-09-17 2004-09-17
US60/610,660 2004-09-17
PCT/IL2005/000990 WO2006030438A2 (en) 2004-09-17 2005-09-15 Use of tellurium compounds for inhibition of interleukin-converting enzyme

Publications (2)

Publication Number Publication Date
CA2580643A1 CA2580643A1 (en) 2006-03-23
CA2580643C true CA2580643C (en) 2018-06-12

Family

ID=35985262

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2580643A Expired - Fee Related CA2580643C (en) 2004-09-17 2005-09-15 Use of tellurium compounds for inhibition of interleukin-converting enzyme
CA2580642A Expired - Fee Related CA2580642C (en) 2004-09-17 2005-09-15 Novel tellurium compounds and their use as immunomodulators
CA002580804A Abandoned CA2580804A1 (en) 2004-09-17 2005-09-15 Compositions and methods for inducing hair growth

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2580642A Expired - Fee Related CA2580642C (en) 2004-09-17 2005-09-15 Novel tellurium compounds and their use as immunomodulators
CA002580804A Abandoned CA2580804A1 (en) 2004-09-17 2005-09-15 Compositions and methods for inducing hair growth

Country Status (10)

Country Link
US (5) US20090269418A1 (https=)
EP (3) EP1796660B1 (https=)
JP (1) JP2008513439A (https=)
AT (1) ATE402709T1 (https=)
AU (1) AU2005283719A1 (https=)
CA (3) CA2580643C (https=)
DE (1) DE602005008622D1 (https=)
ES (2) ES2614113T3 (https=)
PT (1) PT1796660T (https=)
WO (3) WO2006030437A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060341A2 (en) 2003-12-18 2005-07-07 Biomas, Ltd Tellurium derivatives for prevention and treatment of neurodegenerative processes
CA2553803C (en) * 2004-01-22 2015-08-18 Benjamin Sredni Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
ES2614113T3 (es) * 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
EP1841597A4 (en) 2005-01-11 2010-01-27 Jemtex Ink Jet Printing Ltd INK JET PRINTER AND CONTROL METHOD THEREFOR
CA2619073A1 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for protection from ultra-violet radiation
US7973046B2 (en) * 2006-06-01 2011-07-05 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP1862166A1 (en) * 2006-06-01 2007-12-05 Yolanda Rodemer Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
WO2008032227A2 (en) 2006-09-11 2008-03-20 Biomas, Ltd. Topical formulations of tellurium-containing compounds
WO2009066301A2 (en) * 2007-11-23 2009-05-28 Biomas Ltd. Methods and compositions for treating pox virus with tellurium-containing compounds
SI2826371T1 (sl) 2007-11-23 2019-09-30 Feramda Ltd. Metode in sestavki za inhibiranje integrinov z uporabo spojin, ki vsebujejo telur
WO2010079489A1 (en) * 2009-01-08 2010-07-15 Biomas Ltd. Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy
WO2010079488A1 (en) * 2009-01-08 2010-07-15 Biomas Ltd. Tellurium-containing compounds for affecting male's fertility following chemotherapy and/or radiotherapy
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
WO2010146547A1 (en) * 2009-06-16 2010-12-23 Biomas Ltd. Tellurium-containing compounds for facilitating transplantation
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP3617190B1 (en) * 2017-04-28 2023-08-16 Kyoto University Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing vinyl polymer, and vinyl polymer
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
KR20200062242A (ko) * 2017-09-29 2020-06-03 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하는 조성물 및 방법
JP2021042161A (ja) * 2019-09-11 2021-03-18 国立大学法人東海国立大学機構 脱毛剤、脱毛モデル動物及び白髪モデル動物
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) * 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US5102908A (en) 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4962207A (en) * 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US4761490A (en) * 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US4764461A (en) * 1985-09-30 1988-08-16 Bar-Ilan University Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4752614A (en) 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US5093135A (en) 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5271925A (en) 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
US5213899A (en) * 1990-12-17 1993-05-25 General Electric Company Room temperature vulcanizable silicone compositions
US5262149A (en) 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
CN1156962A (zh) 1994-09-01 1997-08-13 法玛西雅厄普约翰公司 替瑞拉得的助溶性胃肠外给药的制剂
US5576347A (en) 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
ATE306927T1 (de) 1994-12-15 2005-11-15 Baker Norton Pharma Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
US5654328A (en) * 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
DK1064298T3 (da) * 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
CN1176941C (zh) * 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
TR200200767T1 (tr) * 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
EP1289993B9 (en) * 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
AU2001218024A1 (en) 2000-06-19 2002-01-02 University Of Southern California Methods for treating and preventing alopecia
AU2002232541A1 (en) * 2000-11-21 2002-06-03 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
JP4428926B2 (ja) * 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
US6472381B1 (en) 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) * 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
PE20040728A1 (es) * 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
TW200500343A (en) * 2002-12-20 2005-01-01 Vertex Pharma Caspase inhibitors and uses thereof
WO2005060341A2 (en) 2003-12-18 2005-07-07 Biomas, Ltd Tellurium derivatives for prevention and treatment of neurodegenerative processes
US9474453B2 (en) * 2004-09-15 2016-10-25 Itamar Medical Ltd. Measuring blood flow and venous capacitance
US20080260770A1 (en) 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
ES2614113T3 (es) 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta

Also Published As

Publication number Publication date
US8623908B2 (en) 2014-01-07
EP1791535B1 (en) 2008-07-30
CA2580642A1 (en) 2006-03-23
ES2312012T3 (es) 2009-02-16
US20100081623A1 (en) 2010-04-01
US20080015175A1 (en) 2008-01-17
WO2006030439A2 (en) 2006-03-23
WO2006030438A3 (en) 2006-05-04
JP2008513439A (ja) 2008-05-01
EP1802292A2 (en) 2007-07-04
CA2580643A1 (en) 2006-03-23
WO2006030437A2 (en) 2006-03-23
EP1791535A2 (en) 2007-06-06
CA2580804A1 (en) 2006-03-23
WO2006030439A3 (en) 2007-05-18
EP1796660B1 (en) 2016-11-23
ES2614113T3 (es) 2017-05-29
ATE402709T1 (de) 2008-08-15
AU2005283719A1 (en) 2006-03-23
CA2580642C (en) 2014-09-02
WO2006030438A2 (en) 2006-03-23
US7709524B2 (en) 2010-05-04
US7652065B2 (en) 2010-01-26
US20090269418A1 (en) 2009-10-29
EP1802292A4 (en) 2008-02-13
US20100233294A1 (en) 2010-09-16
EP1796660A2 (en) 2007-06-20
WO2006030437A3 (en) 2006-06-22
DE602005008622D1 (de) 2008-09-11
EP1796660A4 (en) 2008-01-16
PT1796660T (pt) 2017-02-13
US20070298124A1 (en) 2007-12-27
HK1103355A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
CA2580643C (en) Use of tellurium compounds for inhibition of interleukin-converting enzyme
US9216197B2 (en) Topical formulations of tellurium-containing compounds
US20150023914A1 (en) Use of tellurium compounds for the treatment actinic keratosis
US20100062081A1 (en) Use of tellurium containing compounds as nerve protecting agents
US20170112874A1 (en) Therapeutic Methods And Pharmaceutical Compositions For Treating Warts With Tellurium Compounds
US8080237B2 (en) Use of tellurium compounds for protection from ultra-violet radiation
HK1103355B (en) Novel tellurium compounds and their use as immunomodulators

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210915